Loricam 4 Tablet: Each Film Coated Tablet Contains Lornoxicam INN 4 mg.

Loricam 8 Tablet: Each Film Coated Tablet Contains Lornoxicam INN 8 mg.

INN

Oxicam

Short-term relief of acute mild to moderate pain, symptomatic relief of pain and inflammation in osteoarthritis & symptomatic relief of pain and inflammation in rheumatoid arthritis.

Hypersensitivity to Lornoxicam or to any of the excipients, peptic ulcer, severe hepatic impairment, severe renal impairment (Serum creatinine > 700 µmol/l) and Thrombocytopenia and the third trimester of pregnancy.

Acute Pain: 8-16 mg Lornoxicam daily divided into 2 or 3 doses. Maximum recommended daily dose is 16 mg. Osteoarthritis and Rheumatoid arthritis: Initial recommended dose is 12 mg Lornoxicam daily divided into 2 or 3 doses. Maintenance dose should not exceed 16 mg Lornoxicam daily. 

The most commonly observed adverse events of NSAIDs are gastrointestinal in nature. Peptic ulcers, perforation or GI bleeding, sometimes fatal, particularly in the elderly, may occur. Nausea, vomiting, diarrhea, flatulence, constipation, dyspepsia, abdominal pain, melaena, hematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn’s disease have been reported by following administration of NSAIDs. 

Lornoxicam should be taken carefully when someone has impaired kidney function, someone has a history of high blood pressure or heart failure, someone suffers from ulcerative colitis or Crohn’s diseases, someone has a history of bleeding tendency, someone has a history of asthma & someone suffers from SLE (Systemic Lupus Erythematosus) a rare immunological disease and women who are taking treatment for infertility.

Concomitant administration of Lornoxicam and combination with Vitamin K antagonists like warfarin increases the risk of bleeding. Combination with Cyclosporin can lead to reduced kidney function and to acute kidney injury in rare cases. Lornoxicam can also increase the adverse effects of lithium, methotrexate and digoxin and its derivatives. The effect of diuretics, ACE inhibitors and angiotensin Il receptor antagonists can be reduced in patients with heart failure.

Lornoxicam is not recommended for use in children and adolescents below age 18 due to lack of data on safety and efficacy.

Use in Pregnancy: Lornoxicam is contraindicated on the third trimester of pregnancy and should not be used during pregnancy in the first and second trimesters and delivery, as no clinical data on exposed pregnancies are available.

Use in Lactation: There are no data on the excretion of Lornoxicam in human breast milk. Lornoxicam is excreted in milk of lactating rats in relatively high concentrations. Therefore lornoxicam should not be used in breastfeeding women.

At this time, there is no experience of overdose to permit definition of the consequence of an overdose, or to suggest specific managements. However, it can be expected that after an overdose with Lornoxicam, the following symptoms can be seen: Nausea, vomiting, cerebral symptoms (dizziness, disturbances in vision). In the case of a real or suspected overdose, the medicinal product should be withdrawn. Due to its short half-life, Lornoxicam is rapidly excreted. Lornoxicam is not dialyzable. No specific antidote is known to date. The usual emergency measures including gastric lavage should be considered.

Loricam 4 Tablet: Each Box Contains 3 x 10’s Tablets in blister pack.

Loricam 8 Tablet: Each Box Contains 3 x 10’s Tablets in blister pack.

Store below 30°C. Protect from light and moisture. Keep all medicines out of the reach of children.